Background
Liver fibrosis regression after hepatitis C virus (HCV) cure is variable, especially in advanced cirrhosis. Despite >95% sustained virological response (SVR) rates with direct-acting antivirals (DAAs), long-term risks of decompensation and hepatocellular carcinoma persist, suggesting an “immunological scar.” Determinants of regression remain unclear, particularly in HIV coinfection. We aimed to identify baseline plasma and T-cell biomarkers linked to liver stiffness regression after DAA therapy in people with HIV (PWH) and without HIV (PWoH) and advanced cirrhosis.
Methods
We conducted a prospective multicenter study within the Spanish ESCORIAL cohort including 77 participants with HCV-related advanced cirrhosis (54 PWH, 23 PWoH) who achieved SVR. Liver stiffness measurement (LSM) was assessed by transient elastography at baseline and 48 weeks post-treatment. Plasma cytokines were quantified by multiplex assays, and T-cell immunophenotyping was performed by multiparametric flow cytometry on fresh blood. Associations between baseline biomarkers and longitudinal LSM changes were tested using generalized linear mixed models with Benjamini–Hochberg correction; q<0.20 was significant.
Results
Distinct immunological signatures of regression emerged by HIV status. In PWoH, impaired regression correlated with elevated baseline proinflammatory cytokines (IFN-γ, IL-2, IL-4, IL-17A, IL-1β, TNF-α; all AMR>1, q<0.05) and higher frequencies of terminally differentiated (TemRA) CD4+ T-cells and senescent (CD57+) CD8+ T-cells. Conversely, protective CD127+ TemRA CD8+ T-cells strongly associated with improved regression (AMR:0.72, q=0.002). In PWH, plasma inflammation was not predictive. Instead, impaired regression was linked to dysfunctional Effector Memory (EM) CD4+ T-cells, particularly CD57+ subsets, and activated Central Memory (CM) CD8+ T-cells (all AMR>1, q<0.20). A protective trend was noted for CD127 expression on total CD8+ T-cells (AMR:0.61, q=0.132).
Conclusions
Drivers of liver recovery after HCV cure differ by HIV status. In PWoH, systemic inflammation and T-cell exhaustion dominate, whereas in PWH, baseline memory T-cell functional state prevails. Notably, a protective CD127+ survival phenotype across CD8+ T-cells emerged as a universal marker of improved regression. These results from the Spanish ESCORIAL cohort support immune monitoring as a prognostic tool and highlight CD127+ T-cell preservation as a therapeutic target to optimize hepatic outcomes after viral cure.